| Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784) |
|---|
| 02/21/2002 | WO2002013872A1 Peptide and peptide mimetic conjugates with integrin-inhibitor properties |
| 02/21/2002 | WO2002013858A1 Oral solid dose vaccine |
| 02/21/2002 | WO2002013856A2 W/o emulsion adjuvant compositions for vaccines |
| 02/21/2002 | WO2002013855A2 Vaccines containing ribavirin and methods of use thereof |
| 02/21/2002 | WO2002013846A2 Antifungal combination therapy |
| 02/21/2002 | WO2002013839A1 Animal papilla disinfectants and method of improving microbial environment |
| 02/21/2002 | WO2002013828A1 A retroviral immunotherapy |
| 02/21/2002 | WO2002013816A1 Pharmaceutical composition |
| 02/21/2002 | WO2002013764A2 Methods for treating subjects infected with a herpes virus or neisseria gonorrheae |
| 02/21/2002 | WO2002013763A2 Treatment of hiv-1 infection and inflammatory disease using cyclophilin receptor antagonists |
| 02/21/2002 | WO2001090063A3 Prodrug of an ice inhibitor |
| 02/21/2002 | WO2001085256A3 Critical illness neuropathy |
| 02/21/2002 | WO2001083698A3 Compositions and methods for inducing activation of dendritic cells |
| 02/21/2002 | WO2001079443A3 Albumin fusion proteins |
| 02/21/2002 | WO2001079196A3 1-(h-1,2,4-triazol-1-yl)butan-2-ol derivatives |
| 02/21/2002 | WO2001078533A3 Nutritional modules |
| 02/21/2002 | WO2001077149A3 Regulation of human cyslt2-like gpcr protein |
| 02/21/2002 | WO2001076601A3 Pharmaceutical compositions comprising salmeterol and ipratropium |
| 02/21/2002 | WO2001076554A3 Drug delivery composition and device |
| 02/21/2002 | WO2001074295A3 Phospholipid scramblases and methods of use thereof |
| 02/21/2002 | WO2001072960A3 Il-8 receptor antagonists |
| 02/21/2002 | WO2001072334A3 Methods for treating disease with antibodies to cxcr3 |
| 02/21/2002 | WO2001070807A3 G-protein associated molecules |
| 02/21/2002 | WO2001068802A3 Genes of il-12p40 subunit mutated for improving the activity of il-12 and use thereof for dna vaccine adjuvant |
| 02/21/2002 | WO2001066747A8 Proteins named fctrx and nucleic acids encoding same |
| 02/21/2002 | WO2001066089A3 Pharmaceutical compositions comprising cannabis |
| 02/21/2002 | WO2001064860A3 Recombinant influenza a viruses |
| 02/21/2002 | WO2001062901A3 Pleuripotent stem cells generated from adipose tissue-derived stromal cells and uses thereof |
| 02/21/2002 | WO2001056602A3 Cd40 ligand adjuvant for respiratory syncytial virus |
| 02/21/2002 | WO2001049255A3 Methods and compositions for inhibiting adhesion by microorganisms |
| 02/21/2002 | WO2001043775A3 Hydroxide-releasing agents as skin permeation enhancers |
| 02/21/2002 | WO2001043693A3 Polynucleotide vaccines expressing codon optimized hiv-1 nef and modified hiv-1 nef |
| 02/21/2002 | WO2001039803A3 Interleukin-1 muteins useful as vaccine adjuvants |
| 02/21/2002 | WO2001032631A3 Heterocyclic cytotoxic agents |
| 02/21/2002 | WO2001031005A3 Drosophila g protein coupled receptors, nucleic acids, and methods related to the same |
| 02/21/2002 | WO2001030300A3 Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies |
| 02/21/2002 | WO2001019791A3 3-vinylpyrrole derivatives, method for the production thereof and their use as medicaments |
| 02/21/2002 | WO2000069875A9 C-2 modified erythromycin derivatives |
| 02/21/2002 | WO2000069269A9 Strains of bacteriophage useful for rescuing patients infected with vancomycin-resistant enterococcus faecium |
| 02/21/2002 | WO2000066148A9 Novel proteins |
| 02/21/2002 | WO2000054729A8 Heterocyclic aromatic compounds useful as growth hormone secretagogues |
| 02/21/2002 | US20020022729 Pyridylfuran and pyridylthiophene compounds |
| 02/21/2002 | US20020022722 4'-C-ethynyl pyrimidine nucleoside compounds |
| 02/21/2002 | US20020022718 Genes identified as required for proliferation of E. coli |
| 02/21/2002 | US20020022667 For inducing or maintaining anesthesia or sedation in a patient |
| 02/21/2002 | US20020022660 For disinfecting surfaces, long-lasting antimicrobial activity |
| 02/21/2002 | US20020022659 For therapy of viral infection |
| 02/21/2002 | US20020022654 Method for increasing the concentration of ascorbic acid in brain tissues of a subject |
| 02/21/2002 | US20020022645 Administering benzofuran derivative for therapy of disease state that is capable of being modulated by inhibition of phosphodiesterase IV or Tumour Necrosis Factor |
| 02/21/2002 | US20020022637 Tetrahydroisoquinoline analogs useful as growth hormone secretagogues |
| 02/21/2002 | US20020022635 For therapy of cancer; inflammation; an autoimmune, infectious or ocular disease; or age-related macular degeneration |
| 02/21/2002 | US20020022620 Reverse-turn mimetics and methods relating thereto |
| 02/21/2002 | US20020022619 Administering to the mammal suffering from anxiety, depression and other disorders related to excessive corticotropin releasing factor an effective amount of tricyclic pyridine or pyrimidine derivatives |
| 02/21/2002 | US20020022610 Compositions and methods for treating bacterial infections |
| 02/21/2002 | US20020022600 Azt derivatives exhibiting spermicidal and anti-viral activity |
| 02/21/2002 | US20020022596 Novel malonic acid derivatives, processes for their preparation their use and pharmaceutical compositions containing them |
| 02/21/2002 | US20020022595 Treating inflammation resulting from a response of the non-specific defense system in a mammal by administering an antiinflammatory agent and the uncontaminated Mac-1 alpha subunit |
| 02/21/2002 | US20020022590 Useful as antibiotics; reduced tissue accumulation and/or nephrotoxicity when administered to a mammal; useful against vancomycin-resistant microorganisms |
| 02/21/2002 | US20020022257 Three-dimensional structure and crystallization method of ribosome recycling factor (RRF) |
| 02/21/2002 | US20020022236 Accurately measuring albumin in urine sample; obtain urine, detect presence of adjusted and wildtype albumin in sample |
| 02/21/2002 | US20020022046 Uses for medical devices having a lubricious, nitric oxide-releasing coating |
| 02/21/2002 | US20020022027 Complexing to polypeptides; antiproliferation agent |
| 02/21/2002 | US20020022015 Administration system for seronegative of hepatitis C virus |
| 02/21/2002 | DE10039998A1 Neue substituierte Diareno-azepin-Derivate als Integrin Liganden New substituted Diareno-azepine derivatives as integrin ligands |
| 02/21/2002 | DE10035189A1 Arzneimittel zur oralen Applikation mit einem Gehalt an 3-N-Formylhydroxylaminopropylphosphonsäureestern oder 3-N-Acetylhydroxylaminopropylphosphonsäureestern als Wirkstoff Pharmaceuticals for oral application with a content of 3-N-Formylhydroxylaminopropylphosphonsäureestern or 3-N-Acetylhydroxylaminopropylphosphonsäureestern as an active ingredient |
| 02/21/2002 | CA2685447A1 Pharmaceutical composition |
| 02/21/2002 | CA2431954A1 A retroviral immunotherapy |
| 02/21/2002 | CA2424160A1 Oral solid dose vaccine |
| 02/21/2002 | CA2423337A1 Methods for treating subjects infected with a herpes virus orneisseria gonorrheae |
| 02/21/2002 | CA2419985A1 Modulating multiple lineage kinase proteins |
| 02/21/2002 | CA2419716A1 Plant-derived and synthetic phenolic compounds and plant extracts, effective in the treatment and prevention of chlamydial infections |
| 02/21/2002 | CA2419491A1 Leucine-rich repeat-containing g-protein coupled receptor-8 molecules and uses thereof |
| 02/21/2002 | CA2419418A1 Vaccines containing ribavirin and methods of use thereof |
| 02/21/2002 | CA2418389A1 Pyridine derivatives as inhibitors of p38 |
| 02/21/2002 | CA2418303A1 Treatment of hiv-1 infection and inflammatory disease using cyclophilin receptor antagonists |
| 02/21/2002 | CA2418266A1 Novel mitogen activated kinase |
| 02/21/2002 | CA2418240A1 A disinfectant for teats of animals, and a method for improving microorganism-enviroment harmful for animals |
| 02/21/2002 | CA2387002A1 Non-covalent inhibitors of urokinase and blood vessel formation |
| 02/21/2002 | CA2386081A1 Crystals of penicillin and process for the production thereof |
| 02/20/2002 | EP1180518A1 5-pyridyl-1,3-azole compounds, process for producing the same and use thereof |
| 02/20/2002 | EP1180513A1 Cyclic amide compounds, process for the preparation of the same and uses thereof |
| 02/20/2002 | EP1180164A2 Methods using of fab i and compounds modulating fab i activity |
| 02/20/2002 | EP1180155A1 Vector for integration of heterologous sequences into poxviral genomes |
| 02/20/2002 | EP1180150A2 Nucleic acid immunization |
| 02/20/2002 | EP1180148A1 A VARIANT OF C6 BETA-CHEMOKINE LEUKOTACTIN-1(shLkn-1) WITH ENHANCED BIOLOGICAL ACTIVITY |
| 02/20/2002 | EP1180144A2 Cytoskeleton-associated proteins |
| 02/20/2002 | EP1180119A2 RECOMBINANT $i(HAEMOPHILUS INFLUENZAE) ADHESIN PROTEINS |
| 02/20/2002 | EP1180118A1 Fimbrial proteins |
| 02/20/2002 | EP1180110A1 13-methyl-erythromycin derivatives |
| 02/20/2002 | EP1180109A1 Prodrug activation using catalytic antibodies |
| 02/20/2002 | EP1180105A2 Substituted aza-oxindole derivatives |
| 02/20/2002 | EP1180101A1 Compounds having cytokine inhibitory activity |
| 02/20/2002 | EP1180053A1 Remote and local controlled delivery of pharmaceutical compounds using electromagnetic energy |
| 02/20/2002 | EP1180041A1 Vaccine against isa virus |
| 02/20/2002 | EP1180038A2 Antifungal combination use |
| 02/20/2002 | EP1180033A2 Lamivudine containing pharmaceutical formulation |
| 02/20/2002 | EP1180030A1 Antibacterial compounds |
| 02/20/2002 | EP1180028A1 Il-8 receptor antagonists |
| 02/20/2002 | EP1180025A1 Il-8 receptor antagonists |
| 02/20/2002 | EP1180018A1 Preparations for the application of anti-inflammatory agents |